Summarized by Masters of Longevity from PR Newswire.
Announcement that a late‑stage biotech focused on disease‑modifying neurodegeneration will brief investors about clinical and regulatory progress for its oral ALS therapy.
Key Takeaways
- NeuroSense reported Phase 2b PARADIGM long‑term follow‑up showing slowed functional decline versus placebo.
- The FDA cleared initiation of the pivotal Phase 3 PARAGON ALS trial and the company is optimizing study design.
- PrimeC is an extended‑release oral fixed‑dose combination of ciprofloxacin and celecoxib targeting neuroinflammation and iron dysregulation.
